Rare Disease Phase 1 Deal Benchmarks (2026)

Median upfront of $120M with total deal values reaching $1.7B.

Median Upfront

$120M

Total Deal Value

$1.1B

Royalty Range

5.4%–10.7%

Territory Multiplier

Understanding Rare Disease Deal Benchmarks at Phase 1

Phase 1 Rare Disease licensing deals command a median upfront payment of $120M, with values ranging from $47M at the low end to $200M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the rare disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $531M to $1.7B, with a median of $1.1B. Royalty rates for rare disease assets at this stage typically fall between 5.4% and 10.7% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2023	Vertex Pharmaceuticals	CRISPR Therapeutics	$900M	$1.9B	collaboration
2019	Sarepta Therapeutics	Roche	$1.1B	$2.9B	licensing
2024	Regeneron	Alnylam	$1.0B	$3.4B	collaboration
2018	Ionis Pharmaceuticals	Biogen	$1.0B	$2.6B	collaboration
2024	Argenx	N/A (standalone)	$0M	$2.1B	licensing
2023	Bluebird Bio	N/A (standalone)	$0M	$2.8B	licensing
2024	BioMarin	N/A (standalone)	$0M	$2.9B	licensing
2023	Amicus Therapeutics	N/A (standalone)	$0M	$3.2B	licensing
2024	Ultragenyx	N/A (standalone)	$0M	$800M	licensing
2024	Takeda	N/A (standalone)	$0M	$6.5B	licensing

PRO

See All Comparable Deals

View 10 comparable Rare Disease transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 1 Rare Disease deals?

The median upfront payment for Phase 1 Rare Disease licensing deals is $120M, based on our analysis of comparable transactions. Values range from $47M for early-stage or less differentiated assets up to $200M for premium programs with strong clinical data or first-in-class mechanisms.

How does Global territory affect Rare Disease deal value?

Global rights carry a 1x multiplier relative to base deal economics. This means global rare disease deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 1 Rare Disease licensing?

Royalty rates for Phase 1 rare disease assets typically range from 5.4% to 10.7% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$48M upfront

Rare Disease · Preclinical · Global

$375M upfront

Rare Disease · Phase 2 · Global

$1.3B upfront

Rare Disease · Phase 3 · Global

$3.4B upfront

Rare Disease · Approved · Global

$90M upfront

Oncology · Phase 1 · Global

$76M upfront

Neurology/CNS · Phase 1 · Global

$163M upfront

Immunology · Phase 1 · Global

$229M upfront

Metabolic/Obesity · Phase 1 · Global

Explore More

All Rare Disease Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Rare Disease · Phase 1

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Rare Disease Phase 1 Deal Benchmarks (2026). Retrieved from https://calculator.ambrosiaventures.co/data/rare-disease-phase-1-deals-global

HTML

<a href="https://calculator.ambrosiaventures.co/data/rare-disease-phase-1-deals-global">Rare Disease Phase 1 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$47M	$120M	$200M
Total Deal Value	$531M	$1.1B	$1.7B
Royalty Rate	5.4%	—	10.7%